OrthoPediatrics (NASDAQ:KIDS) Given New $35.00 Price Target at Needham & Company LLC

OrthoPediatrics (NASDAQ:KIDS) had its target price increased by equities researchers at Needham & Company LLC from $30.00 to $35.00 in a research note issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price objective indicates a potential upside of 67.62% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. Canaccord Genuity Group set a $25.00 target price on OrthoPediatrics in a research note on Friday, April 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Friday, July 17th. BTIG Research reissued a “buy” rating and issued a $24.00 price target on shares of OrthoPediatrics in a report on Friday, May 1st. Truist Financial upped their price objective on OrthoPediatrics from $17.00 to $20.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Finally, TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $25.33.

OrthoPediatrics Trading Up 0.0%

NASDAQ:KIDS opened at $20.88 on Wednesday. OrthoPediatrics has a 52-week low of $14.42 and a 52-week high of $22.80. The company has a quick ratio of 2.37, a current ratio of 5.21 and a debt-to-equity ratio of 0.29. The stock has a fifty day simple moving average of $19.08 and a 200-day simple moving average of $17.82. The company has a market capitalization of $536.20 million, a PE ratio of -12.43 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS) last posted its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. The firm had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative net margin of 16.31% and a negative return on equity of 7.01%. On average, equities research analysts expect that OrthoPediatrics will post -1.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On OrthoPediatrics

Several hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. grew its position in shares of OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after purchasing an additional 1,139 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in OrthoPediatrics by 5,226.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after buying an additional 2,561 shares during the period. Caption Management LLC acquired a new stake in OrthoPediatrics in the 3rd quarter worth about $54,000. BNP Paribas Financial Markets boosted its stake in OrthoPediatrics by 60.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after buying an additional 1,235 shares during the last quarter. Finally, State of Wyoming grew its holdings in OrthoPediatrics by 189.7% in the 4th quarter. State of Wyoming now owns 6,822 shares of the company’s stock valued at $121,000 after buying an additional 4,467 shares during the period. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.